ACS Medicinal Chemistry Letters
Letter
(13) Selten, G.; Cuypers, H. T.; Berns, A. Proviral activation of the
putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO
J. 1985, 4 (7), 1793−8.
bioavailable inhibitors of the human protooncogene proviral insertion
site in moloney murine leukemia virus (PIM) kinases. J. Med. Chem.
2009, 52 (21), 6621−36.
(30) Nishiguchi, G. A.; Atallah, G.; Bellamacina, C.; Burger, M. T.;
Ding, Y.; Feucht, P. H.; Garcia, P. D.; Han, W.; Klivansky, L.; Lindvall,
M. Discovery of novel 3,5-disubstituted indole derivatives as potent
inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg. Med.
Chem. Lett. 2011, 21, 6366−9.
(31) Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.;
Tang, C. Synthesis and biological evaluations of 3-substituted indolin-
2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity
toward particular receptor tyrosine kinases. J. Med. Chem. 1998, 41
(14), 2588−603.
(32) Kim, K. T.; Levis, M.; Small, D. Constitutively activated FLT3
phosphorylates BAD partially through pim-1. Br. J. Hamaetol. 2006,
134 (5), 500−9.
(33) Kim, K. T.; Baird, K.; Ahn, J. Y.; Meltzer, P.; Lilly, M.; Levis, M.;
Small, D. Pim-1 is up-regulated by constitutively activated FLT3 and
plays a role in FLT3-mediated cell survival. Blood 2005, 105 (4),
1759−67.
(34) Zheng, H. C.; Tsuneyama, K.; Takahashi, H.; Miwa, S.;
Sugiyama, T.; Popivanova, B. K.; Fujii, C.; Nomoto, K.; Mukaida, N.;
Takano, Y. Aberrant Pim-3 expression is involved in gastric adenoma-
adenocarcinoma sequence and cancer progression. J. Cancer Res. Clin.
Oncol. 2008, 134 (4), 481−8.
(35) Popivanova, B. K.; Li, Y. Y.; Zheng, H.; Omura, K.; Fujii, C.;
Tsuneyama, K.; Mukaida, N. Proto-oncogene, Pim-3 with serine/
threonine kinase activity, is aberrantly expressed in human colon
cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci. 2007,
98 (3), 321−8.
(14) Li, Y. Y.; Popivanova, B. K.; Nagai, Y.; Ishikura, H.; Fujii, C.;
Mukaida, N. Pim-3, a proto-oncogene with serine/threonine kinase
activity, is aberrantly expressed in human pancreatic cancer and
phosphorylates bad to block bad-mediated apoptosis in human
pancreatic cancer cell lines. Cancer Res. 2006, 66 (13), 6741−7.
(15) Wang, Z.; Bhattacharya, N.; Mixter, P. F.; Wei, W.; Sedivy, J.;
Magnuson, N. S. Phosphorylation of the cell cycle inhibitor p21Cip1/
WAF1 by Pim-1 kinase. Biochim. Biophys. Acta 2002, 1593 (1), 45−55.
(16) Mochizuki, T.; Kitanaka, C.; Noguchi, K.; Muramatsu, T.; Asai,
A.; Kuchino, Y. Physical and functional interactions between Pim-1
kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated
activation of the c-Myc signaling pathway. J. Biol. Chem. 1999, 274
(26), 18659−66.
(17) Morishita, D.; Katayama, R.; Sekimizu, K.; Tsuruo, T.; Fujita, N.
Pim kinases promote cell cycle progression by phosphorylating and
down-regulating p27Kip1 at the transcriptional and posttranscriptional
levels. Cancer Res. 2008, 68 (13), 5076−85.
(18) Bachmann, M.; Kosan, C.; Xing, P. X.; Montenarh, M.;
Hoffmann, I.; Moroy, T. The oncogenic serine/threonine kinase Pim-
1 directly phosphorylates and activates the G2/M specific phosphatase
Cdc25C. Int. J. Biochem. Cell Biol. 2006, 38 (3), 430−43.
(19) Dhanasekaran, S. M.; Barrette, T. R.; Ghosh, D.; Shah, R.;
Varambally, S.; Kurachi, K.; Pienta, K. J.; Rubin, M. A.; Chinnaiyan, A.
M. Delineation of prognostic biomarkers in prostate cancer. Nature
2001, 412 (6849), 822−6.
(20) Morwick, T. Pim kinase inhibitors: a survey of the patent
literature. Expert Opin. Ther. Pat. 2010, 2, 193−212.
(21) Ren, J. X.; Li, L. L.; Zheng, R. L.; Xie, H. Z.; Cao, Z. X.; Feng, S.;
Pan, Y. L.; Chen, X.; Wei, Y. Q.; Yang, S. Y. Discovery of novel Pim-1
kinase inhibitors by a hierarchical multistage virtual screening
approach based on SVM model, pharmacophore, and molecular
docking. J. Chem. Inf. Model. 2011, 51 (6), 1364−75.
(22) Xiang, Y.; Hirth, B.; Asmussen, G.; Biemann, H. P.; Bishop, K.
A.; Good, A.; Fitzgerald, M.; Gladysheva, T.; Jain, A.; Jancsics, K.; Liu,
J.; Metz, M.; Papoulis, A.; Skerlj, R.; Stepp, J. D.; Wei, R. R. The
discovery of novel benzofuran-2-carboxylic acids as potent Pim-1
inhibitors. Bioorg. Med. Chem. Lett. 2011, 21, 3050−6.
(23) Pierce, A. C.; Jacobs, M.; Stuver-Moody, C. Docking study
yields four novel inhibitors of the protooncogene Pim-1 kinase. J. Med.
Chem. 2008, 51 (6), 1972−5.
(24) Pogacic, V.; Bullock, A. N.; Fedorov, O.; Filippakopoulos, P.;
Gasser, C.; Biondi, A.; Meyer-Monard, S.; Knapp, S.; Schwaller, J.
Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase
inhibitors with in vitro antileukemic activity. Cancer Res. 2007, 67 (14),
6916−24.
(25) Grey, R.; Pierce, A. C.; Bemis, G. W.; Jacobs, M. D.; Moody, C.
S.; Jajoo, R.; Mohal, N.; Green, J. Structure-based design of 3-aryl-6-
amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. Bioorg.
Med. Chem. Lett. 2009, 19 (11), 3019−22.
(26) Bullock, A. N.; Debreczeni, J. E.; Fedorov, O. Y.; Nelson, A.;
Marsden, B. D.; Knapp, S. Structural basis of inhibitor specificity of the
human protooncogene proviral insertion site in moloney murine
leukemia virus (PIM-1) kinase. J. Med. Chem. 2005, 48 (24), 7604−14.
(27) Holder, S.; Zemskova, M.; Zhang, C.; Tabrizizad, M.; Bremer,
R.; Neidigh, J. W.; Lilly, M. B. Characterization of a potent and
selective small-molecule inhibitor of the PIM1 kinase. Mol. Cancer
Ther. 2007, 6 (1), 163−72.
(28) Cheney, I. W.; Yan, S.; Appleby, T.; Walker, H.; Vo, T.; Yao, N.;
Hamatake, R.; Hong, Z.; Wu, J. Z. Identification and structure-activity
relationships of substituted pyridones as inhibitors of Pim-1 kinase.
Bioorg. Med. Chem. Lett. 2007, 17 (6), 1679−83.
(29) Tao, Z. F.; Hasvold, L. A.; Leverson, J. D.; Han, E. K.; Guan, R.;
Johnson, E. F.; Stoll, V. S.; Stewart, K. D.; Stamper, G.; Soni, N.;
Bouska, J. J.; Luo, Y.; Sowin, T. J.; Lin, N. H.; Giranda, V. S.;
Rosenberg, S. H.; Penning, T. D. Discovery of 3H-benzo[4,5]thieno-
[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally
139
dx.doi.org/10.1021/ml200259q | ACS Med. Chem. Lett. 2012, 3, 135−139